Projects granted by the Ministry of Economy and Competitiveness of the Government of Spain, in which Reig Jofre participates:
| Project title: | POLYCYSTIC OVARY SYNDROME (PCOS) IN ADOLESCENT GIRLS AND YOUNG WOMEN: TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY. (SPIOMET4HEALTH) |
| Reference Number: | 899671 |
| Partners: | FUNDACIÓ SANT JOAN DE DÉU/HOSPITAL SANT JOAN DE DÉU UNIVERSIDAD KU LEUVEN, FUNDACIÓ INSTITUT D’INVESTIGACIÓ BIOMÈDICA DE GIRONA DOCTOR JOSEP TRUETA, UNIVERSIDAD WITTEN/HERDECKE, UNIVERSIDAD MÉDICA DE GRAZ, REGION SYDDANMARK, UNIVERSIDAD NORUEGA DE CIENCIA Y TECNOLOGÍA, UNIVERSIDAD ALMA MATER STUDIORUM DE BOLONIA, UNIVERSIDAD DE ISTANBUL, OPTIMAPHARM, LABORATORIO REIG JOFRE SA, UNIVERSIDAD COMPLUTENSE DE MADRID, OUTCOMES’10 SL, INSTITUTO EUROPEO DE LA SALUD DE LA MUJER, LA DELEGACIÓN DE LA UE “MAKE MOTHERS MATTER”, ASPHALION SL Y ZABALA INNOVATION. |
| Funding Agency: | This project has received funding from the European Union’s Horizon 2020 research and innovation program.
|
| Objetive: | The main objective of SPIOMET4HEALTH is to test, in a multi-centre Phase II clinical trial, a novel treatment for adolescent girls and young adult women with PCOS. |
| Duration: | 2021-2026 |
| Project title: | DEVELOPMENT OF THE FIRST INTERNATIONAL VALIDATED VACCINE AGAINST ANTIBIOTIC-RESISTANT PNEUMONIA. (STOPINFECTIONS) |
| Reference number: | RTC2019-007058-1 |
| Partners: | VAXDYN S.L. LABORATORIO REIG JOFRE, S.A ACONDICIONAMIENTO TARRASENSE LEITAT INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII) |
| Funding Agency: | Ministry of Science, Innovation and Universities funded this project within the Challenges & Collaboration Subprogram, Call 2019. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research.  |
| Objective: | The main objective of the project is to complete the preclinical development and request permission to enter the clinical phase in humans of KAPAVAX, the first universal trivalent vaccine against infections caused by the bacteria Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii, the three highest pathogens priority among antibiotic resistant for the World Health Organization, against which there is no vaccine in the clinical stages of development. |
| Duration: | 2020-2022 |
| Project title: | DEVELOPMENT OF NEW NANOTECHNOLOGICAL THERAPIES FOR FOLLICULAR RELEASE APPLIED TO ALOPECIA (ALOSTOP) |
| Reference number: | RTC2019-007035-1 |
| Partners: | Laboratorio Reig Jofre S.A. Fundación para la investigación biomédica del Hospital Univ. Ramon Y Cajal Bionos Biotech Fundación Bosch i Gimpera |
| Funding Agency: | Ministry of Science, Innovation and Universities funded this project within the Challenges & Collaboration Subprogram, Call 2019. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research. |
| Objective: | The main objective of the project is to bring to an exploratory clinical study an innovative treatment more effective than the current ones for the treatment of alopecia. |
| Duration: | 2020-2023 |
| Project title: | USE OF MUCOADHESIVE POLYMERIC FORMULATIONS FOR THE ERADICATION OF HELICOBACTER PYLORI (PYLOMUC) |
| Reference number: | RTC-2017-6643-1 |
| Partners: | Laboratorio Reig Jofre S.A. Bionanoplus S.L. Universidad de Navarra Universidad de Sevilla |
| Funding Agency: | Ministry of Science, Innovation and Universities funded this project within the Challenges & Collaboration Subprogram, Call 2017. The project is co-funded by the European Union with the aim of promoting technological development, innovation and quality research.  |
| Objective: | The main objective of the project is to develop innovative formulations based on mucoadhesive polymeric systems for the treatment of gastric ulcers caused by Helicobacter pylori infection. |
| Duration: | 2018-2021 |
| Project title: | TRANSITION TO CLINICAL INVESTIGATION PHASE FOR LICENSE OF THE FIRST VACCINE AGAINST DRUG RESISTANT ACINETOBACTER BAUMANNII (ACINETOCLINIC) |
| Reference number: | RTC-2016- 5161-1 |
| Partners: | Vaxdyn Laboratorio Reig Jofre SA Draconis Pharma Instituto de Biomedicina de Sevilla (IBIS) Hospital Universitario Virgen del Rocío (HUVR) Centro Tecnológico Leitat |
| Funding Agency: | Ministry of Economy and Competitiveness, co-financed through EU-FEDER funds, within the State Program 2016 Challenges & Colaboration of the State Research Agency, with the main objective of Promoting technological development, innovation and quality research. |
| Objective: | Complete the transition to clinical development in humans (Phase I in healthy volunteers) of the first universal vaccine against infections caused by bacteria resistant to Acinetobacter baumannii antibiotics (VxD-001 vaccine). |
| Duration: | 2016-2019 |
| Project title: | DEVELOPMENT OF NEW APPROACHES IN THE INDIVIDUALIZED MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS (PredictGYN) |
| Reference number: | RTC-2015-3821-1 |
| Partners: | Ability Pharmaceuticals SL Althia Health SL Fundacio Hospital Universitari Vall d’Hebron – Institut de Recerca Institut de Recerca Biomedica de Lleida Fundacio Privada Dr. Pifarre Laboratorio Reig Jofre SA Oryzon Genomics Diagnostico SL |
| Funding Agency: | Ministry of Economy and Competitiveness, within the State Program of Research, Development and Innovation Oriented to the Challenges of Society under the State Plan of Scientific and Technical Research, and Innovation 2013-2016.  |
| Objective: | Identification of molecular markers to develop a prognostic test for patients with endometrial and ovarian cancer. Development of new personalized therapy strategies in endometrial cancer. |
| Duration: | 2015-2018 |
| Project title: | DEVELOPMENT OF INNOVATIVE FORMULATIONS OF MUCOADHESIVE NANOPARTICLES FOR THE TREATMENT OF MUCOSAL ULCERS (NANOMUC) |
| Reference number: | RTC-2015-4437-1 |
| Partners: | Bionanoplus SL Laboratorio Reig Jofre SA Universidad de Navarra Universidad de Sevilla |
| Funding Agency: | Ministry of Economy and Competitiveness, within the State Program of Research, Development and Innovation Oriented to the Challenges of Society under the State Plan of Scientific and Technical Research, and Innovation 2013-2016. |
| Objective: | Development of controlled drug release treatments using innovative formulations of mucoadhesive polymeric nanoparticles. This will allow a longer residence of active principles in the mucous, combining local and systemic action, and resulting in a more effective treatment. |
| Duration: | 2015-2017 |
| Project title: | CURE4B |
| Reference number: | RTC-2015-4319-1 |
| Partners: | Fundacio per a la recerca i la docencia Sant Joan de Deu (FSJD) Institut Catala d’Oncologia Laboratorio Reig Jofre SA Vcn Biosciences SL |
| Funding Agency: | Ministry of Economy and Competitiveness, within the State Program of Research, Development and Innovation Oriented to the Challenges of Society under the State Plan of Scientific and Technical Research, and Innovation 2013-2016. |
| Objective: | Development and validation of oncolytic virus VCN-01 as a clinical candidate for retinoblastoma treatment, the most common type of eye cancer in children. |
| Duration:: | 2015-2018 |
| Project title: | DEVELOPMENT OF HIGH EFFICIENCY SYSTEMS FOR THE PRODUCTION OF BIOSIMILAR ANTIBODIES, ANTI-VEGF (SIMBIO) |
| Reference number: | Expediente: IPT-2012-0663-090000 |
| Partners: | Laboratorio Reig Jofre SA Bioingenium Centro Tecnologico Leitat |
| Funding Agency: | Ministry of Economy and Competitiveness, National Program of Public-Private Cooperation – INNPACTO subprogram, within the instrumental line of Articulation and Internationalization of the System, under the National Plan for Scientific Research, Development, and Technological Innovation 2008-2011. |
| Objective: | Optimize the production of anti-VEGF biosimilars. Production of the biosimilar of the active principle Ranibizumab, using E coli, and optimization of a eukaryotic cells platform for therapeutic proteins expression. |
| Duration: | 2012-2015 |
| Project title: | ADENOVIRUS WITHOUT ISOTOPES FOR VACCINATION (ADELVAC) |
| Reference number: | IPT-2012-0551-010000 |
| Partners: | VCN Biosciences SL Laboratorio Reig Jofre SA ICO ISC III |
| Funding Agency: | Ministry of Economy and Competitiveness, National Program of Public-Private Cooperation – INNPACTO subprogram, within the instrumental line of Articulation and Internationalization of the System, under the National Plan for Scientific Research, Development, and Technological Innovation 2008-2011. |
| Objective: | Developing a new generation of vaccines based on adenovirus devoid of intrinsic immunogenicity, due to the withdraw of immunodominant epitopes, thus preventing activation of the immune system. New vectors carrying the appropriate antigens may be used for both therapeutic approach of chemoresistant tumors and treatment of infectious diseases. |
| Duration: | 2012-2014 |
Projects in collaboration with scientific societies and research groups:
| Project title: | Social-health research program for physiological solutions of seawater |
| Partners: | Spanish Society of Outpatient Pediatrics and Primary Care (SEPEAP) Spanish Society of Allergology and Clinical Immunology (SEAIC) Spanish Society of Otorhinolaryngology (SEORL) Laboratorio Reig Jofre SA |
| Methodology & Objectives: | Study on the specialists’ opinion in the use of seawater (presentation and decalogue available only in Spanish):
Survey of seawater users (presentation available only in Spanish):
|
| Duration: | 2016-2017 |
| Project title: | Transcultural validation in Spanish of the scale HAIR SPECIFIC SKINDEX 29 |
| Partners: | Complutense University of Madrid Hospital 12 de Octubre of Madrid University of Granada University of Barcelona Hospital Clínic of Barcelona Laboratorio Reig Jofre SA |
| Objective: | Obtaining and cross-cultural validation of the first scale in Spanish capable of measuring the evolution of the quality of life in the female alopecia treatment. Project presentation at the conference of the Spanish Academy of Dermatology and Venereology (available only in Spanish):
Paper in the journal of the Spanish Academy of Dermatology Actas Dermo-Sifiliográficas (Abstract in English) |
| Duration: | 2016-2017 |